克隆氏症:KOL Insight

AbbVie的Skyrizi的有效性高，不过，限制其使用与治疗流程发展的课题是什么？在口服sufingoshinmojureta的领域，专家怎么评价与BMS的Zeposia和Pfizer的etrasimod竞争的优点，怎样的要素对处方带来影响？

本报告提供克隆氏症市场调查，市售的治疗药和开发平台预测评价。授权用户，可阅览报告全文，以及附件区域的Report Highlights slidedeck和以下的KOL Bulletins。

目录

摘要整理

今后的治疗流程

调查目的

• 成药
  • TNF抑制剂(Remicade，Humira，Cimzia)
  • entibio(vedolizumab; Takeda)
  • Stelara(ustekinumab; Johnson & Johnson)
  • Tysabri(natalizumab; Biogen)
  • sukiriji(risankizumab; AbbVie)
• 开发平台医药品
  • Tremfya (guselkumab; Janssen Biotech)
  • Mirikizumab (Eli Lilly)
  • Brazikumab (AstraZeneca)
  • Rinvoq (upadacitinib; AbbVie)
  • Jyseleca (filgotinib; Galapagos/Gilead Sciences)
  • Zeposia (ozanimod; Bristol Myers Squibb)
  • Etrasimod (Pfizer)

今后的治疗趋势

• 重要的洞察的彙整
  • 克隆氏症的未来治疗策略，有转移到JAK抑制剂，p19s第1或第2线的可能性

附录

• 关于KOL
  • 北美的KOLs
  • 欧洲的KOLs

KOLs are impressed with the efficacy of AbbVie's Skyrizi but what challenges do they identify that could limit its use and progress in the treatment algorithm? In the oral sphingosine modulator sector, how do experts assess the competing merits of BMS' Zeposia and Pfizer's etrasimod and what factors will influence prescribing? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and the following KOL Bulletins via the Attachments area.

Table of Contents

Executive Summary (1)

Future treatment algorithm

Research objectives (303)

• Marketed drugs (178)
  • TNF inhibitors (Remicade, Humira, Cimzia) (55)
  • Entyvio (vedolizumab; Takeda) (43)
  • Stelara (ustekinumab; Johnson & Johnson) (39)
  • Tysabri (natalizumab; Biogen) (14)
  • Skyrizi (risankizumab; AbbVie) (27)

• Pipeline drugs (124)
  • Tremfya (guselkumab; Janssen Biotech) (19)
  • Mirikizumab (Eli Lilly) (16)
  • Brazikumab (AstraZeneca) (13)
  • Rinvoq (upadacitinib; AbbVie) (38)
  • Jyseleca (filgotinib; Galapagos/Gilead Sciences) (16)
  • Zeposia (ozanimod; Bristol Myers Squibb) (18)
  • Etrasimod (Pfizer) (4)

Future treatment trends (24)

• Key insights summary (24)
  • Future treatment strategies for Crohn's disease could see JAK inhibitors, p19s move up to first or second line (24)

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe